Edesa Biotech, Inc. (EDSA) stock forecast & analysis
2.15
NasdaqCM · USDDelayed by 15 minutes
Down: -0.34, -13.6%
1 analysis
Latest analysis: · verdict locked
- Open
- 2.31
- Previous close
- 2.49
- Day range
- 1.92 – 2.34
- 52-week range
- 0.7200 – 20.32
- Volume (shares)
- 1.25M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 13.51M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.24
- Market cap
- 29.05M
Market Scanner’s AI analysis of Edesa Biotech, Inc. (EDSA), updated November 2026: Edesa Biotech's recent analyses focused on significant price declines, negative financial trends, and liquidity metrics.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Edesa Biotech, Inc. (EDSA) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Edesa Biotech's recent analyses focused on significant price declines, negative financial trends, and liquidity metrics.
Recent analyses for Edesa Biotech (EDSA) examined its substantial stock price depreciation over the past 91 days, with the current price trading below key moving averages. The reports also covered the company's consistent net losses, decreasing shareholder equity, and increasing debt. Despite negative operating cash flow, short-term liquidity appears adequate based on current and quick ratios.
EDSA news & sentiment
No recent news was found for Edesa Biotech. Social media discussion was not covered in the provided notes.
EDSA technical picture
The stock price has experienced significant declines, trading substantially below its 50-day and 200-day simple moving averages, indicating a bearish trend. Momentum readings, including the 10-day EMA and MACD, also confirmed bearish momentum, while RSI approached oversold territory, showing a lack of buying pressure.
Fundamentals
The company has consistently reported net losses, with a widening loss in the most recent quarter. Shareholder equity has decreased while total debt has increased. Despite negative operating cash flow, short-term liquidity appears adequate based on current and quick ratios.
Factors discussed — upside
- Money Flow Index (MFI) exceptionally high at 99.57
- Current Ratio of 2.757 suggests adequate short-term liquidity
- Quick Ratio of 2.701 suggests adequate short-term liquidity
- Total cash of $10,332,520 USD
Factors discussed — risks
- Stock price declined -29.1% in 30 days and -52.5% in 91 days
- Price below 50-day SMA ($3.50) and 200-day SMA ($5.68)
- RSI at 39.84, approaching oversold territory
- MACD is negative at -0.3624
- Consistently reported net losses
- Technical price trends
- Financial performance
- Liquidity and cash flow
- Shareholder equity
Summary updated .
EDSA technical indicators
Common technical indicators for EDSA, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 3.45 | Price below |
| 10-day exponential moving average | 2.36 | Price below |
| Relative strength index (14-day) | 33.34 | Neutral |
| MACD line (12/26/9) | -0.3603 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 2.07 – 3.00 | Price inside the bands |
Analyses
Recent EDSA.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-10 EDSA.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Edesa Biotech, Inc.?
- The Money Flow Index (MFI) registered exceptionally high at 99.57, suggesting strong buying pressure. Additionally, the company's current ratio of 2.757 and quick ratio of 2.701 indicate adequate short-term liquidity, supported by $10,332,520 USD in total cash.
- What are the risks for Edesa Biotech, Inc.?
- The company's stock has experienced significant declines, with a 30-day change of -29.1% and a 91-day change of -52.5%, trading below its 50-day and 200-day simple moving averages. The Relative Strength Index (RSI) is approaching oversold territory at 39.84, and the MACD is negative at -0.3624, confirming bearish momentum. Analyses also noted consistent net losses, decreasing shareholder equity, and increasing debt.
- Is Edesa Biotech, Inc. bullish or bearish?
- Recent AI analyses of Edesa Biotech, Inc. examined factors on both sides. Discussed upside: The Money Flow Index (MFI) registered exceptionally high at 99.57, suggesting strong buying pressure. Additionally, the company's current ratio of 2.757 and quick ratio of 2.701 indicate adequate short-term liquidity, supported by $10,332,520 USD in total cash. Discussed risks: The company's stock has experienced significant declines, with a 30-day change of -29.1% and a 91-day change of -52.5%, trading below its 50-day and 200-day simple moving averages. The Relative Strength Index (RSI) is approaching oversold territory at 39.84, and the MACD is negative at -0.3624, confirming bearish momentum. Analyses also noted consistent net losses, decreasing shareholder equity, and increasing debt. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Edesa Biotech, Inc.?
- No recent news was found for Edesa Biotech. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Edesa Biotech, Inc.?
- Every analysis of Edesa Biotech, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Edesa Biotech, Inc.?
The Money Flow Index (MFI) registered exceptionally high at 99.57, suggesting strong buying pressure. Additionally, the company's current ratio of 2.757 and quick ratio of 2.701 indicate adequate short-term liquidity, supported by $10,332,520 USD in total cash.
What are the risks for Edesa Biotech, Inc.?
The company's stock has experienced significant declines, with a 30-day change of -29.1% and a 91-day change of -52.5%, trading below its 50-day and 200-day simple moving averages. The Relative Strength Index (RSI) is approaching oversold territory at 39.84, and the MACD is negative at -0.3624, confirming bearish momentum. Analyses also noted consistent net losses, decreasing shareholder equity, and increasing debt.
Is Edesa Biotech, Inc. bullish or bearish?
Recent AI analyses of Edesa Biotech, Inc. examined factors on both sides. Discussed upside: The Money Flow Index (MFI) registered exceptionally high at 99.57, suggesting strong buying pressure. Additionally, the company's current ratio of 2.757 and quick ratio of 2.701 indicate adequate short-term liquidity, supported by $10,332,520 USD in total cash. Discussed risks: The company's stock has experienced significant declines, with a 30-day change of -29.1% and a 91-day change of -52.5%, trading below its 50-day and 200-day simple moving averages. The Relative Strength Index (RSI) is approaching oversold territory at 39.84, and the MACD is negative at -0.3624, confirming bearish momentum. Analyses also noted consistent net losses, decreasing shareholder equity, and increasing debt. These are descriptive observations, not a recommendation.
What is the latest sentiment on Edesa Biotech, Inc.?
No recent news was found for Edesa Biotech. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Edesa Biotech, Inc.?
Every analysis of Edesa Biotech, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh EDSA.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.